Capricor Therapeutics Stock Forecast, Price & News

Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions

Is Capricor Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Capricor Therapeutics stock.
View analyst ratings for Capricor Therapeutics or view top-rated stocks.

How has Capricor Therapeutics' stock price been impacted by COVID-19?

Capricor Therapeutics' stock was trading at $1.0050 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CAPR shares have increased by 194.5% and is now trading at $2.96.
View which stocks have been most impacted by COVID-19.

When is Capricor Therapeutics' next earnings date?

Capricor Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Capricor Therapeutics.

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) released its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.05. Capricor Therapeutics had a negative net margin of 5,621.25% and a negative trailing twelve-month return on equity of 53.48%. During the same quarter in the prior year, the firm posted ($0.20) EPS.
View Capricor Therapeutics' earnings history.

What price target have analysts set for CAPR?

2 Wall Street analysts have issued 1 year target prices for Capricor Therapeutics' shares. Their forecasts range from $12.00 to $14.00. On average, they anticipate Capricor Therapeutics' share price to reach $13.00 in the next year. This suggests a possible upside of 339.2% from the stock's current price.
View analysts' price targets for Capricor Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the following people:

• Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
• Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
• Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
• Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
• Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
• Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
• Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
• Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
• Deborah Ascheim M.D., Chief Medical Officer
• Joshua A. Kazam, Director (Age 40)

Who are some of Capricor Therapeutics' key competitors?

Some companies that are related to Capricor Therapeutics include Aerovate Therapeutics (AVTE), Kamada (KMDA), MEI Pharma (MEIP), Verrica Pharmaceuticals (VRCA), Nanobiotix (NBTX), ZIOPHARM Oncology (ZIOP), Applied Therapeutics (APLT), Connect Biopharma (CNTB), Immutep (IMMP), 89bio (ETNB), Akouos (AKUS), Sernova (SEOVF), BioDelivery Sciences International (BDSI), Atossa Therapeutics (ATOS) and Homology Medicines (FIXX).
View all of CAPR's competitors.

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

Who are Capricor Therapeutics' major shareholders?

Capricor Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.30%), Geode Capital Management LLC (0.89%), Citadel Advisors LLC (0.00%), GSA Capital Partners LLP (0.42%), HighTower Advisors LLC (0.23%) and Morgan Stanley (0.22%).
View institutional ownership trends for Capricor Therapeutics.

Which institutional investors are selling Capricor Therapeutics stock?

CAPR stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, and BlackRock Inc..
View insider buying and selling activity for Capricor Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Capricor Therapeutics stock?

CAPR stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, HighTower Advisors LLC, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Geode Capital Management LLC, Two Sigma Securities LLC, Morgan Stanley, and Barclays PLC.
View insider buying and selling activity for Capricor Therapeutics or or view top insider-buying stocks.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $2.96.

How much money does Capricor Therapeutics make?

Capricor Therapeutics has a market capitalization of $71.48 million and generates $310 thousand in revenue each year. The biotechnology company earns $-13.66 million in net income (profit) each year or ($0.82) on an earnings per share basis.

What is Capricor Therapeutics' official website?

The official website for Capricor Therapeutics is www.capricor.com.

Where are Capricor Therapeutics' headquarters?

Capricor Therapeutics is headquartered at 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200, via email at [email protected], or via fax at 415-875-7075.